Holen Sie sich die Stockscreener-App
34.26
0.53%
0.18
Handel nachbörslich:
34.10
-0.16
-0.47%
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Is Castle Biosciences Inc (CSTL) Overvalued After 3.9% Rally? GF - GuruFocus
CFO & Treasurer Of Castle Biosciences Sold 41% Of Their Shares - Sahm
Castle Biosciences to Participate in Upcoming Investor Conferences - Sahm
238,204 Shares in Castle Biosciences, Inc. $CSTL Acquired by Advisors Capital Management LLC - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Castle Biosciences CCO Tobin W Juvenal Sells 1,730 Shares via 10b5-1 Trading Plan - Kalkine Media
Castle (CSTL) Results Versus Estimates: EPS Beats Its Estimate in the Current Update; After Earnings: The Stock Ends Up 5.75% for the Current SessionEarnings Season Outlook - vinanet.vn
Castle Biosciences CFO Frank Stokes Sells 24,908 Shares in Open Market Transaction - Kalkine Media
Castle Biosciences (CSTL) CFO sells 24,908 company shares - Stock Titan
Castle Biosciences (CSTL) Edges Lower to $29.66: Diagnostic Stock Holds Key Support ZoneProfitability Factor - vinanet.vn
Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas - marketscreener.com
Castle Biosciences gains dual listing on Nasdaq Texas By Investing.com - Investing.com Australia
Castle Biosciences gains dual listing on Nasdaq Texas - Investing.com
Castle Biosciences Approved for Dual Listing on Nasdaq Texas - PR Newswire
AIGH Capital Management LLC Buys Shares of 545,101 Castle Biosciences, Inc. $CSTL - MarketBeat
Quantinno Capital Management LP Purchases 36,144 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
Is Castle Biosciences Inc (CSTL) a Bargain After 3.0% Drop? GF V - GuruFocus
CSTL (CSTL) files notice to sell 24,908 common shares on NASDAQ - Stock Titan
CSTL (CSTL) insider and family trusts detail planned and recent stock sales - Stock Titan
Wasatch Advisors LP Sells 175,687 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction - MarketBeat
Castle Biosciences at canaccord growth conference: growth broadens - Investing.com
Castle Biosciences (CSTL) Inches Higher as Shares Hold Above Key SupportIV Contraction - Vinanet
Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring a 44% Upside Potential in the Diagnostics Sector - DirectorsTalk Interviews
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 20,356 Shares of Stock - MarketBeat
Tobin Juvenal Sells 1,301 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - marketbeat.com
Castle Biosciences (NASDAQ:CSTL) COO Sells 8,586 Shares of Stock - MarketBeat
Dimensional Fund Advisors LP Sells 104,038 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 19,040 Shares - GuruFocus
Castle Biosciences (CSTL) Pulls Back 2.5% to $30.40, Holding Above Key SupportPercent Above MA - Vinanet
Castle Biosciences (NASDAQ:CSTL) Insider Sells 1,730 Shares - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells $323,652.40 in Stock - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 6,480 Shares - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 17,310 Shares of Stock - MarketBeat
BTIG raises Castle Biosciences stock price target on strong revenue - Investing.com
BTIG Research Forecasts Strong Price Appreciation for Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Castle Biosciences (CSTL) Jumps 4.5% as Shares Approach Key $29.4 ResistanceCharm Flow - Vinanet
CFO Awards honoree Frank Stokes of Castle Biosciences Inc. - The Business Journals
Renaissance Technologies LLC Has $13.08 Million Stock Holdings in Castle Biosciences, Inc. $CSTL - MarketBeat
Form 144 Castle Biosciences For: 1 August By Investing.com - Investing.com Nigeria
Castle Biosciences, Inc. Stock 12‑Month Price Target Raised to $43.56, Implies 63% Upside - tradingview.com
Castle Biosciences Stock Price Forecast. Should You Buy CSTL? - StockInvest.us
CSTL (CSTL) insider schedules potential $630,000 sale of 22,500 shares - Stock Titan
Castle Biosciences, Inc. (CSTL) Stock Analysis: Unpacking a 59.68% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Castle Biosciences Inc (CSTL) Institutional Confidence - TradingKey
Earnings Flash (CSTL) Castle Biosciences Posts Q2 Revenue of $103.5 Million, vs. FactSet Est of $86.2 Million - marketscreener.com
Earnings call transcript: Castle Biosciences tops Q2 2026 estimates, shares jump - Investing.com
Is Castle Biosciences (CSTL) Undervalued After Q2 Earnings Miss? GF Score: 81/100, Revenue at $103.5 Million - GuruFocus
Q2 2026 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Castle Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Castle Biosciences Reports Second Quarter 2026 Results - PR Newswire
Castle Biosciences Raises FY26 Sales Guidance to $365-$375 Million - scanx.trade
Castle Biosciences CEO Maetzold sells $237,682 in company stock By Investing.com - Investing.com Canada
Form 4 Castle Biosciences Inc For: 29 July By Investing.com - Investing.com Canada
Castle Biosciences Gains 2.39% as Stock Tests Resistance Near $25.68Chart Pattern Alerts - vinanet.vn
Castle Biosciences Edges Lower, Testing Key Support Zone (CSTL)Combination Correction - vinanet.vn
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Castle Biosciences Inc (CSTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Castle Biosciences Inc (CSTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Castle Biosciences Inc (CSTL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Castle Biosciences Inc (CSTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Castle Biosciences Inc (CSTL) Cash Flow - TradingKey
Earnings Preview: CSTL to Report Financial Results Post-market on July 30 - Moomoo
Castle Biosciences Inc (CSTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Castle Biosciences, Inc. (CSTL) Investor Outlook: Exploring A 67.89% Potential Upside - DirectorsTalk Interviews
CSTL|Castle Biosciences Inc|Price:25.093|Chg%:-0.387 - TradingKey
Castle Biosciences sets live webcast for Aug. 12 conference - Stock Titan
New York State Department of Health Approves Castle’s AdvanceAD-Tx Test - The Dermatology Digest
0.24%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):